Evidence map›Paper›PMID 37631373›Full record

ArticlePharmaceutics2023

Anticholinesterase and Serotoninergic Evaluation of Benzimidazole-Carboxamides as Potential Multifunctional Agents for the Treatment of Alzheimer's Disease.

Daria A Belinskaia, Polina A Voronina, Denis V Krivorotov, Richard O Jenkins, Nikolay V Goncharov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Serotonergic Regulation in Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  2. Novel Emerging Targets Identification in Reducing Risk of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Daria A BelinskaiaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez 44, St. Petersburg 194223, Russia.
Polina A VoroninaSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez 44, St. Petersburg 194223, Russia.
Denis V KrivorotovResearch Institute of Hygiene, Occupational Pathology and Human Ecology, Federal Medical Biological Agency, p.o. Kuzmolovsky, St. Petersburg 188663, Russia.
Richard O JenkinsLeicester School of Allied Health Sciences, De Montfort University, The Gateway, Leicester LE1 9BH, UK.
Nikolay V GoncharovSechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, Thorez 44, St. Petersburg 194223, Russia.
Institute of Evolutionary Physiology and Biochemistry · RUDe Montfort University · GBFederal Medical-Biological Agency · RU

Funding

Institute of Evolutionary Physiology and Biochemistry 075-00967-23-00
6 · The paper itself

Abstract

The etiology and pathogenesis of Alzheimer's disease are multifactorial, so one of the treatment strategies is the development of the drugs that affect several targets associated with the pathogenesis of the disease. Within this roadmap, we investigated the interaction of several substituted 1,3-dihydro-2-oxo-1

Indexed as

Alzheimer’s diseasebenzimidazolonesbiochemical analysischolinesterasesmolecular dockingmolecular dynamicsserotonin receptors

Identifiers

PMID37631373
PMCPMC10459044
OpenAlexW4386029808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.